Sequential study of TET2 mutations and JAK2^V617F in patient P4 (F3) in mononuclear cells and committed progenitors. (A) Sequence electrophorograms are shown for each TET2 mutation and for JAK^V617F. (Left diagram) The different phases of the disease with their time lapse from diagnosis. (Right diagram) The disease duration (in years) at each sample date. Allele burdens of TET2 mutations and JAK2^V617F, semiquantitatively estimated by sequencing as Bellanne-Chantelot et al,²  are indicated. (B) Histograms show for PV and acute leukemia (AL) phases the 3 distinct TET2 genotypes (each bar corresponding to a specific genotype, wt/wt, 550X/wt, 550X/857fs). The JAK2^V617F mutation was absent, heterozygous, or homozygous. The number of genotyped clones is indicated for each group.